8639 related articles for article (PubMed ID: 14731050)
1. Health economic evaluation of non-melanoma skin cancer and actinic keratosis.
Higashi MK; Veenstra DL; Langley PC
Pharmacoeconomics; 2004; 22(2):83-94. PubMed ID: 14731050
[TBL] [Abstract][Full Text] [Related]
2. Pharmacoeconomic considerations in treating actinic keratosis.
Neidecker MV; Davis-Ajami ML; Balkrishnan R; Feldman SR
Pharmacoeconomics; 2009; 27(6):451-64. PubMed ID: 19640009
[TBL] [Abstract][Full Text] [Related]
3. CONSENSUS REPORT: Recognizing non-melanoma skin cancer, including actinic keratosis, as an occupational disease - A Call to Action.
John SM; Trakatelli M; Gehring R; Finlay K; Fionda C; Wittlich M; Augustin M; Hilpert G; Barroso Dias JM; Ulrich C; Pellacani G
J Eur Acad Dermatol Venereol; 2016 Apr; 30 Suppl 3():38-45. PubMed ID: 26995022
[TBL] [Abstract][Full Text] [Related]
4. Economic evaluation of methyl aminolaevulinate-based photodynamic therapy in the management of actinic keratosis and basal cell carcinoma.
Caekelbergh K; Annemans L; Lambert J; Roelandts R
Br J Dermatol; 2006 Oct; 155(4):784-90. PubMed ID: 16965429
[TBL] [Abstract][Full Text] [Related]
5. Awareness, knowledge and attitudes to non-melanoma skin cancer and actinic keratosis among the general public.
Halpern AC; Kopp LJ
Int J Dermatol; 2005 Feb; 44(2):107-11. PubMed ID: 15689206
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of a photolyase-based device in the treatment of cancerization field in patients with actinic keratosis and non-melanoma skin cancer.
Puviani M; Barcella A; Milani M
G Ital Dermatol Venereol; 2013 Dec; 148(6):693-8. PubMed ID: 24442053
[TBL] [Abstract][Full Text] [Related]
7. Non-melanoma Skin Cancer in Canada Chapter 1: Introduction to the Guidelines.
Guenther LC; Barber K; Searles GE; Lynde CW; Janiszewski P; Ashkenas J;
J Cutan Med Surg; 2015; 19(3):205-15. PubMed ID: 26016676
[TBL] [Abstract][Full Text] [Related]
8. Non-melanoma skin cancer in Australia.
Fransen M; Karahalios A; Sharma N; English DR; Giles GG; Sinclair RD
Med J Aust; 2012 Nov; 197(10):565-8. PubMed ID: 23163687
[TBL] [Abstract][Full Text] [Related]
9. Pharmacoeconomic Considerations in Treating Actinic Keratosis: An Update.
Vale SM; Hill D; Feldman SR
Pharmacoeconomics; 2017 Feb; 35(2):177-190. PubMed ID: 27785771
[TBL] [Abstract][Full Text] [Related]
10. Topical therapies for skin cancer and actinic keratosis.
Haque T; Rahman KM; Thurston DE; Hadgraft J; Lane ME
Eur J Pharm Sci; 2015 Sep; 77():279-89. PubMed ID: 26091570
[TBL] [Abstract][Full Text] [Related]
11. Estimating the health care costs of non-melanoma skin cancer in Saskatchewan using physician billing data.
Tran DA; Coronado AC; Sarker S; Alvi R
Curr Oncol; 2019 Apr; 26(2):114-118. PubMed ID: 31043813
[TBL] [Abstract][Full Text] [Related]
12. The economic impact of non-melanoma skin cancer: a review.
Mudigonda T; Pearce DJ; Yentzer BA; Williford P; Feldman SR
J Natl Compr Canc Netw; 2010 Aug; 8(8):888-96. PubMed ID: 20870635
[TBL] [Abstract][Full Text] [Related]
13. Non-Melanoma Skin Cancer in Outdoor Workers: A Study on Actinic Keratosis in Italian Navy Personnel.
Vimercati L; De Maria L; Caputi A; Cannone ESS; Mansi F; Cavone D; Romita P; Argenziano G; Di Stefani A; Parodi A; Peris K; Scalvenzi M; Girolomoni G; Foti C
Int J Environ Res Public Health; 2020 Mar; 17(7):. PubMed ID: 32235587
[TBL] [Abstract][Full Text] [Related]
14. Real-life practice study of the clinical outcome and cost-effectiveness of photodynamic therapy using methyl aminolevulinate (MAL-PDT) in the management of actinic keratosis and basal cell carcinoma.
Annemans L; Caekelbergh K; Roelandts R; Boonen H; Leys C; Nikkels AF; van Den Haute V; van Quickenborne L; Verhaeghe E; Leroy B
Eur J Dermatol; 2008; 18(5):539-46. PubMed ID: 18693157
[TBL] [Abstract][Full Text] [Related]
15. Actinic keratosis: a cross-sectional study of disease characteristics and treatment patterns in Danish dermatology clinics.
Erlendsson AM; Egekvist H; Lorentzen HF; Philipsen PA; Stausbøl-Grøn B; Stender IM; Haedersdal M
Int J Dermatol; 2016 Mar; 55(3):309-16. PubMed ID: 26276415
[TBL] [Abstract][Full Text] [Related]
16. Characteristics of office-based visits for skin cancer. Dermatologists have more experience than other physicians in managing malignant and premalignant skin conditions.
Smith ES; Feldman SR; Fleischer AB; Leshin B; McMichael A
Dermatol Surg; 1998 Sep; 24(9):981-5. PubMed ID: 9754086
[TBL] [Abstract][Full Text] [Related]
17. [Therapeutic modalities and economic assessment in the treatment of superficial basal cell carcinomas and multiple actinic keratoses by French dermatologists].
Bernard P; Dupuy A; Brun P; Sasko A; Duru G; Nicoloyannis N; Decuypere L; Grob JJ
Ann Dermatol Venereol; 2007; 134(6-7):527-33. PubMed ID: 17657178
[TBL] [Abstract][Full Text] [Related]
18. Optical coherence tomography imaging of non-melanoma skin cancer undergoing photodynamic therapy reveals subclinical residual lesions.
Themstrup L; Banzhaf CA; Mogensen M; Jemec GB
Photodiagnosis Photodyn Ther; 2014 Mar; 11(1):7-12. PubMed ID: 24280439
[TBL] [Abstract][Full Text] [Related]
19. Dermoscopy in the diagnosis and management of non-melanoma skin cancers.
Fargnoli MC; Kostaki D; Piccioni A; Micantonio T; Peris K
Eur J Dermatol; 2012; 22(4):456-63. PubMed ID: 22534287
[TBL] [Abstract][Full Text] [Related]
20. Awareness of, knowledge of and attitudes to nonmelanoma skin cancer (NMSC) and actinic keratosis (AK) among physicians.
Halpern AC; Hanson LJ
Int J Dermatol; 2004 Sep; 43(9):638-42. PubMed ID: 15357741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
